Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference
February 06 2015 - 1:00PM
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D.
Meldrum, president and CEO of Myriad Genetics, is scheduled to
present at the Leerink Global Healthcare Conference at 1:00 p.m.
Eastern on February 12, 2015, at the Waldorf Astoria in New York,
New York.
The presentation will be available to interested parties through
a live audio webcast accessible through a link in the investor
relations section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad's
molecular diagnostic tests are based on an understanding of the
role genes play in human disease and were developed with a
commitment to improving an individual's decision making process for
monitoring and treating disease. Myriad is focused on strategic
directives to introduce new products, including companion
diagnostics, as well as expanding internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysisCDx, HRD, Vectra and Prolaris are trademarks or
registered trademarks of Myriad Genetics, Inc. in the United States
and foreign countries. MYGN-F, MYGN-G
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024